Copay Underfunding Pushes Retina Patients to Cheaper Drugs

A 2025 survey of 455 retina specialists finds nearly all are concerned about how underfunded copay assistance is affecting patients.

Updated on Nov. 13, 2026 in Healthcare

Bold flat-color editorial illustration of unlabeled glass vials and a syringe set on a matte surface, suggesting a cost-driven shift between treatments.
Specialists report switching patients to cheaper bevacizumab after underfunded copay assistance programs for retina drugs left many patients facing higher out-of-pocket costs. AI Illustration. Upload story photo >

Live Poll

Do you think prescription copays are making it harder for you to get care?

A 2025 survey of 455 American Society of Retina Specialists members found 99% were concerned about the patient impact of underfunded copay assistance programs, and 94% reported a disruption in care. Specialists reported switching patients to less expensive therapies, most commonly bevacizumab.

Why it matters

Higher patient copays can limit access to care and adherence to recommended therapies for vision-threatening eye diseases. Specialists say the shift to cheaper alternatives may also raise the risk of vision loss in the United States.

Among diabetic macular edema patients in the lowest income quartile, switches to bevacizumab rose from 3.9% in 2024 to 9.5% in 2025. The survey covered 455 specialists, and the 2025 switching rate and downstream outcomes remain under study.

The players

American Society of Retina Specialists

A professional society representing retina specialists, the eye physicians who treat conditions such as macular degeneration and diabetic macular edema.

Good Days

A copay assistance program that helps patients cover out-of-pocket costs for vitreoretinal disease treatments.

The details

Ophthalmologists reported switching patients with wet age-related macular degeneration or diabetic macular edema to bevacizumab, and discontinuing treatment for some patients with geographic atrophy. Good Days, a copay assistance program for vitreoretinal diseases, said it was underfunded two years ago, and 84% of ophthalmologists reported increased injection frequency after switching therapies.

Timeline

  1. 2024: Baseline year for the lowest-income diabetic macular edema bevacizumab switching rate.

  2. 2025: Retina specialist survey conducted and the 2025 switching rate measured.

  3. Two years ago: Good Days announced its copay assistance program was underfunded.

Health Landscape

The Cleveland Clinic real-world study examined 89 eyes of 69 patients, and the Vestrum database study included 329,786 eyes, together forming a growing body of real-world evidence on retina treatment access. These findings add to a broader picture in which cost barriers shape which therapies patients receive for vision-threatening disease.

Patients who face higher copays may be moved to less expensive alternatives, which can change their injection schedules. Missed follow-up visits caused by financial hardship can delay care for serious eye disease.

The takeaway

Affordability is a clinical issue as well as a financial one for patients with retina disease. Patients facing high out-of-pocket costs should raise cost concerns with their eye doctor early so that alternatives and assistance can be considered before treatment is interrupted.

Further reading

Explore more on Healthcare coverage of drug costs and patient access.

Source note: This article includes information reported by Healio.

Live Poll

Do you think prescription copays are making it harder for you to get care?